×
Inovio Pharmaceuticals Price/Book Ratio 2010-2024 | INO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
Inovio Pharmaceuticals price/book ratio from 2010 to 2024. Price/book ratio can be defined as
View More
Inovio Pharmaceuticals Price/Book Ratio 2010-2024 | INO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
Inovio Pharmaceuticals price/book ratio from 2010 to 2024. Price/book ratio can be defined as
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$149.8B
Vertex Pharmaceuticals (VRTX)
$120.3B
Bristol Myers Squibb (BMY)
$115.2B
Gilead Sciences (GILD)
$110.2B
CSL (CSLLY)
$85.5B
Regeneron Pharmaceuticals (REGN)
$83.7B
GSK (GSK)
$69.8B
Argenex SE (ARGX)
$34B
Alnylam Pharmaceuticals (ALNY)
$30B
BioNTech SE (BNTX)
$24.4B
Biogen (BIIB)
$23B
Illumina (ILMN)
$20.7B
BeiGene (BGNE)
$18.3B
Moderna (MRNA)
$15.2B
Incyte (INCY)
$14.8B
Genmab (GMAB)
$13.7B
Insmed (INSM)
$11.9B
BioMarin Pharmaceutical (BMRN)
$11.8B
Vaxcyte (PCVX)
$10.8B
Bio-Techne Corp (TECH)
$10.6B
Sarepta Therapeutics (SRPT)
$10B
Exelixis (EXEL)
$9.9B
Bio-Rad Laboratories (BIO.B)
$9.4B
QIAGEN (QGEN)
$9.4B
Exact Sciences (EXAS)
$9.2B
Revolution Medicines (RVMD)
$9.1B
Intra-Cellular Therapies (ITCI)
$8.7B
Roivant Sciences (ROIV)
$8.3B
Ascendis Pharma (ASND)
$7.4B
Repligen (RGEN)
$6.9B